Diversified Trust Co increased its position in shares of Pfizer Inc. (NYSE:PFE) by 13.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 27,801 shares of the biopharmaceutical company’s stock after purchasing an additional 3,248 shares during the quarter. Diversified Trust Co’s holdings in Pfizer were worth $987,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in PFE. BlackRock Inc. lifted its stake in Pfizer by 2.8% during the fourth quarter. BlackRock Inc. now owns 452,745,609 shares of the biopharmaceutical company’s stock worth $16,398,445,000 after purchasing an additional 12,183,218 shares during the last quarter. Mackenzie Financial Corp lifted its stake in Pfizer by 29,164.7% during the fourth quarter. Mackenzie Financial Corp now owns 11,481,988 shares of the biopharmaceutical company’s stock worth $415,878,000 after purchasing an additional 11,442,753 shares during the last quarter. Amundi Pioneer Asset Management Inc. lifted its stake in Pfizer by 81.3% during the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 19,093,990 shares of the biopharmaceutical company’s stock worth $691,583,000 after purchasing an additional 8,563,358 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Pfizer by 11.9% during the fourth quarter. Bank of New York Mellon Corp now owns 70,738,885 shares of the biopharmaceutical company’s stock worth $2,562,162,000 after purchasing an additional 7,534,957 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in Pfizer by 11.9% during the first quarter. Dimensional Fund Advisors LP now owns 47,174,487 shares of the biopharmaceutical company’s stock worth $1,674,223,000 after purchasing an additional 4,998,981 shares during the last quarter. Hedge funds and other institutional investors own 69.04% of the company’s stock.

Several equities analysts recently issued reports on the company. Cantor Fitzgerald initiated coverage on Pfizer in a research note on Thursday, June 7th. They set an “overweight” rating and a $45.00 price objective on the stock. Credit Suisse Group raised their target price on Pfizer from $39.00 to $40.00 and gave the company a “neutral” rating in a research note on Wednesday, August 1st. Jefferies Financial Group reiterated a “neutral” rating and issued a $39.00 target price on shares of Pfizer in a research note on Monday, May 14th. BMO Capital Markets cut their target price on Pfizer from $43.00 to $42.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 2nd. Finally, JPMorgan Chase & Co. reiterated a “buy” rating and issued a $42.00 target price on shares of Pfizer in a research note on Thursday. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the company. Pfizer presently has a consensus rating of “Hold” and a consensus target price of $41.53.

Shares of PFE opened at $42.40 on Friday. The firm has a market cap of $250.97 billion, a PE ratio of 16.00, a price-to-earnings-growth ratio of 2.04 and a beta of 0.96. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.41. Pfizer Inc. has a one year low of $33.20 and a one year high of $42.77.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, July 31st. The biopharmaceutical company reported $0.81 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.07. The company had revenue of $13.47 billion for the quarter, compared to analyst estimates of $13.30 billion. Pfizer had a return on equity of 25.35% and a net margin of 42.35%. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period last year, the company earned $0.67 earnings per share. sell-side analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 4th. Stockholders of record on Friday, August 3rd will be issued a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.21%. The ex-dividend date of this dividend is Thursday, August 2nd. Pfizer’s dividend payout ratio (DPR) is 51.32%.

In other news, insider Laurie J. Olson sold 10,214 shares of the firm’s stock in a transaction on Monday, August 13th. The stock was sold at an average price of $41.00, for a total transaction of $418,774.00. Following the transaction, the insider now directly owns 72,672 shares of the company’s stock, valued at $2,979,552. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director W Don Cornwell sold 5,223 shares of the firm’s stock in a transaction on Monday, June 4th. The shares were sold at an average price of $36.40, for a total value of $190,117.20. The disclosure for this sale can be found here. Insiders have sold 785,453 shares of company stock worth $29,937,357 over the last three months. Corporate insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Featured Article: Understanding Average Daily Trade Volume

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.